Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

NCT02184195 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02184195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02184195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
December 16, 2014
Completion date
January 27, 2023
Enrollment
154 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

germline brca1/2 mutations and, metastatic adenocarcinoma of the pancreas